Clinical Trial Update: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating aprepitant-based triple regimen for prevention of chemotherapy-induced nausea and vomiting in the first cycle of moderately em…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Aprepitant-based triple regimen (aprepitant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nausea, Vomiting | Phase 4 | Status: COMPLETED | Results posted: 2015-07-30